Skip to main content
  • Login
  • Contact
  • Subscriptions

Search form

Home

Deer Park Tribune

Deer Park weather

  • Home
  • News
  • Sports
  • Obituaries
  • Entertainment
    • Special Sections
    • Talking About...
  • Photos
  • Videos
  • Classifieds
    • Classified Display Ads
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

23.59 USD -0.36 (-1.50%)
Official Closing Price Updated: 5:43 PM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,721,000
Open 23.91
Bid (Size) 23.29 (5)
Ask (Size) 23.75 (24)
Prev. Close 23.95
Today's Range 23.39 - 24.11
52wk Range 18.18 - 27.80
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors
April 05, 2021
Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability,... 
From Business Wire News Releases
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcin
March 31, 2021
Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line... 
From Business Wire News Releases

Performance

YTD
+14.91%
+14.91%
1 Month
+0.81%
+0.81%
3 Month
N/A
N/A
6 Month
+4.47%
+4.47%
1 Year
+0.04%
+0.04%

More News

Read More
Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanc
March 30, 2021
From Business Wire News Releases
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Ur
March 18, 2021
From Business Wire News Releases
Royalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK
April 01, 2021
Tags M&A Market News TAK
From Benzinga
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
March 08, 2021
From Business Wire News Releases
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
February 26, 2021
From Business Wire News Releases
3 Growth Stocks That'll Make You Richer in Q2 (and Beyond)
April 08, 2021
Tags Market News ZM EXEL
From Motley Fool
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March
February 25, 2021
From Business Wire News Releases
June 18th Options Now Available For Exelixis (EXEL)
March 26, 2021
Tags Stocks
From Market News Video
Sum Up The Parts: IUSG Could Be Worth $101
March 26, 2021
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2020 The Deer Park Tribune | 104 N. Main Street | Deer Park, WA 99006 | (509) 276-5043
All property rights for the entire contents of this publication shall be the property of The Deer Park Tribune.
No part hereof may be reproduced without prior written consent.
Privacy and Terms of Use


Site Design, Programming & Development by Surf New Media